HP802-247: Difference between revisions
mNo edit summary |
m decapitalize category names |
||
| Line 1: | Line 1: | ||
HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb | HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb | ||
| last= | |last= | ||
| first= | |first= | ||
| date=2012-08-03 | |date=2012-08-03 | ||
| title=Spray-on-skin' treatment for leg ulcers | |title=Spray-on-skin' treatment for leg ulcers | ||
| url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | |url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | ||
| publisher=NHS | |publisher=NHS | ||
| accessdate=2012-11-24 | |accessdate=2012-11-24 | ||
}}</ref> | }}</ref> | ||
| Line 13: | Line 13: | ||
The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb | The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb | ||
| last= | |last= | ||
| first= | |first= | ||
| date=201209 | |date=201209 | ||
| title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | |title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | ||
| url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract | |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract | ||
| publisher=The Lancet | |publisher=The Lancet | ||
| accessdate=2012-11-24 | |accessdate=2012-11-24 | ||
}}</ref> | }}</ref> | ||
| Line 26: | Line 26: | ||
{{REF}} | {{REF}} | ||
[[Category:Foreskin | [[Category:Foreskin products]] | ||
[[Category:Financial | [[Category:Financial gain]] | ||
[[Category:From CircLeaks]] | [[Category:From CircLeaks]] | ||
[[Category:From IntactWiki]] | [[Category:From IntactWiki]] | ||